This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic (HOLX) Launches Novodiag System for On-Demand Testing
by Zacks Equity Research
Hologic (HOLX) introduces the Novodiag system in Europe for on-demand testing of infectious diseases and antimicrobial resistance.
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
by Zacks Equity Research
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $117.91, marking a +1.22% move from the previous day.
Abbott (ABT) Gets FDA Nod for Amplatzer Talisman System
by Zacks Equity Research
The Amplatzer Talisman PFO Occlusion System from Abbott (ABT) is used to treat patients with a patent foramen ovale and are at risk of recurrent ischemic stroke.
Abbott (ABT) Stock Moves -1.53%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $118.74, moving -1.53% from the previous trading session.
3 Promising MedTech Stocks to Snap Up in Second-Half 2021
by Trina Mukherjee
Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $124.65 in the latest trading session, marking a -0.38% move from the prior day.
Abbott's (ABT) Portico With FlexNav System Gets FDA Approval
by Zacks Equity Research
Abbott's (ABT) Portico with FlexNav TAVR system is intended to treat people with symptomatic severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Abbott (ABT) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $127.44 in the latest trading session, marking a -0.04% move from the prior day.
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
by Riya Anand
Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.
Abbott (ABT) Nutrition Sales Grow Despite Pandemic Woes
by Zacks Equity Research
Abbott's (ABT) Sales of Pedialyte, the global rehydration brand, strongly grows driven by the recently launched products and increased investments in direct consumer promotion.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $128.80, moving +0.64% from the previous trading session.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given a strong second-quarter performance and strength in the Structural Heart business.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Intel, Qualcomm, Shopify and TJX Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Intel, Qualcomm, Shopify and TJX Companies
Top Stock Reports for Abbott, Intel & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), Intel Corporation (INTC), and QUALCOMM Incorporated (QCOM).
Abbott (ABT) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on solid second-quarter performance and continued adoption of FreeStyle Libre worldwide.
Abbott (ABT) Expands Vascular Portfolio With New Acquisition
by Zacks Equity Research
Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.
Abbott's (ABT) Heart Failure Device Study Outcome Favorable (Revised)
by Zacks Equity Research
Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $127.40 in the latest trading session, marking a +0.82% move from the prior day.
Abbott's (ABT) Amplatzer Amulet Occluder Trial Data Favorable
by Zacks Equity Research
Abbott's (ABT) Amulet IDE trial findings supported the recent FDA approval of Abbott's Amplatzer Amulet LAA Occluder to reduce the risk of stroke in patients with atrial fibrillation.
Abbott's (ABT) Heart Failure Device Study Outcome Favorable
by Zacks Equity Research
Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $125.47, marking a +0.59% move from the previous day.
Abbott's (ABT) Base Volume Rebounds, Lowered View Concerns
by Zacks Equity Research
Abbott's (ABT) Diabetes Care business has been in the limelight for developments in its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Abbott (ABT) Receives FDA Nod for Amplatzer Amulet Device
by Zacks Equity Research
The FDA's go-ahead for Abbott's (ABT) Amulet will offer a unique treatment option in the United States that seals off the left atrial appendage entirely without any blood-thinning drugs.
Abbott (ABT) Receives FDA Approval for OCT Imaging Platform
by Zacks Equity Research
The FDA authorization for Abbott's (ABT) OCT imaging platform powered by the Ultreon Software is expected to broaden its accessibility to physicians.